Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:BLTE NASDAQ:MIRM NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$88.33-1.3%$84.47$34.34▼$95.32$5.54B0.621.02 million shs1.30 million shsBLTEBelite Bio$138.16+1.0%$154.12$56.10▼$200.00$5.49B-1.24235,207 shs154,909 shsMIRMMirum Pharmaceuticals$99.35-0.2%$97.89$47.89▼$114.99$6.07B0.5734,841 shs553,578 shsVIRVir Biotechnology$8.61+1.1%$9.46$4.16▼$11.66$1.44B1.651.58 million shs1.18 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+8.20%-0.97%+7.92%+24.48%+110.89%BLTEBelite Bio+0.17%-5.27%-12.02%-16.61%+123.98%MIRMMirum Pharmaceuticals+5.89%+7.62%-6.87%+9.79%+105.41%VIRVir Biotechnology+3.27%-6.89%-9.36%-7.99%+62.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$88.33-1.3%$84.47$34.34▼$95.32$5.54B0.621.02 million shs1.30 million shsBLTEBelite Bio$138.16+1.0%$154.12$56.10▼$200.00$5.49B-1.24235,207 shs154,909 shsMIRMMirum Pharmaceuticals$99.35-0.2%$97.89$47.89▼$114.99$6.07B0.5734,841 shs553,578 shsVIRVir Biotechnology$8.61+1.1%$9.46$4.16▼$11.66$1.44B1.651.58 million shs1.18 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+8.20%-0.97%+7.92%+24.48%+110.89%BLTEBelite Bio+0.17%-5.27%-12.02%-16.61%+123.98%MIRMMirum Pharmaceuticals+5.89%+7.62%-6.87%+9.79%+105.41%VIRVir Biotechnology+3.27%-6.89%-9.36%-7.99%+62.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.74Moderate Buy$114.5629.70% UpsideBLTEBelite Bio 2.63Moderate Buy$203.0046.93% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$138.3639.26% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.88142.45% UpsideCurrent Analyst Ratings BreakdownLatest VIR, BLTE, MIRM, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/11/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/8/2026APGEApogee Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $97.006/3/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$20.00 ➝ $21.006/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.006/1/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$89.005/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/27/2026APGEApogee Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$83.00 ➝ $81.005/27/2026APGEApogee Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$137.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/ABLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/AMIRMMirum Pharmaceuticals$521.31M11.62$0.05 per share1,952.56$6.12 per share16.23VIRVir Biotechnology$68.56M21.18N/AN/A$5.50 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)BLTEBelite Bio-$77.61M-$2.53N/A114.18N/AN/A-13.14%-12.88%8/10/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A431.96N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)VIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)Latest VIR, BLTE, MIRM, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59BLTEBelite BioN/A33.7133.71MIRMMirum Pharmaceuticals1.282.091.99VIRVir BiotechnologyN/A7.117.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BLTEBelite Bio0.53%MIRMMirum PharmaceuticalsN/AVIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%BLTEBelite Bio13.29%MIRMMirum Pharmaceuticals8.32%VIRVir Biotechnology2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableBLTEBelite Bio1040.08 million34.76 millionNot OptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableVIRVir Biotechnology580168.65 million163.76 millionOptionableVIR, BLTE, MIRM, and APGE HeadlinesRecent News About These CompaniesMorgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00June 11 at 8:46 AM | marketbeat.comVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10 at 6:10 PM | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10 at 4:05 PM | businesswire.comWINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIRJune 10 at 7:23 AM | marketbeat.comBarclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Given New $21.00 Price Target at Leerink PartnersJune 4, 2026 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00June 3, 2026 | marketbeat.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comVir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026 - SlideshowMay 30, 2026 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by AnalystsMay 28, 2026 | marketbeat.comSF Biotech Boss Slashes Labs, Bets Big On Cancer In High-Stakes Vir MakeoverMay 27, 2026 | hoodline.comHUBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIRMay 27, 2026 | marketbeat.comHow SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment StoryMay 25, 2026 | finance.yahoo.comWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMay 23, 2026 | aol.comAVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL ...May 19, 2026 | finance.yahoo.comVir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 MillionMay 19, 2026 | finance.yahoo.comVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026May 18, 2026 | businesswire.comVir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMay 17, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026VIR, BLTE, MIRM, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$88.33 -1.17 (-1.31%) Closing price 04:00 PM EasternExtended Trading$88.34 +0.01 (+0.01%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Belite Bio NASDAQ:BLTE$138.16 +1.31 (+0.96%) Closing price 04:00 PM EasternExtended Trading$138.10 -0.06 (-0.04%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Mirum Pharmaceuticals NASDAQ:MIRM$99.35 -0.19 (-0.19%) Closing price 04:00 PM EasternExtended Trading$99.37 +0.02 (+0.02%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Vir Biotechnology NASDAQ:VIR$8.61 +0.09 (+1.06%) Closing price 04:00 PM EasternExtended Trading$8.58 -0.03 (-0.33%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
